WCIO 2008 and Best of ASCO^®
June 22 - 25, 2008
Hyatt Regency Century Plaza
Los Angeles, CA, USA

2008 Schedule-at-a-Glance ( 210kb)

View Best of ASCO® Sessions

SUNDAY, June 22, 2008
7:45 am – 8:00 am		Welcome Address 225kb
8:00 am - 10:00 am		Multimodality Session I: Co-Chairs: Mike Choti, Jordan Berlin, Daniel Brown, Luigi Solbiati COLORECTAL LIVER METASTASES (15 min. presentations) 1. Systemic Chemotherapy in Colorectal Cancer: Advances and Integration with Locoregional Therapy 1.35mb Jordan Berlin 2. Expanding the Role of Liver Resection in the Management of Liver Metastases 9.3mb Michael Choti 3. Intraoperative Ablation: Indications and Results 460kb Sandra Wong 4. Percutaneous Ablation of Liver Metastases 5.5mb Luigi Solbiati 5. Transarterial Chemoembolization for Hepatic Colorectal Metastases 16.9mb Thierry Debaere 6. Transarterial Radioembolization for Colorectal Metastases Riad Salem 7. Selected ASCO/WCIO Abstracts (5 Minute Presentations with 10 minute discussion at the end of the abstracts) A1. (67) Transarterial Chemoembolization (TACE of liver metastases (LM) from colorectal carcinoma (CRC) adopting Drug Eluting Beads Preloaded with Irinotecan: Report of 62 Patients C. Aliberti1, G. Benea1, M. Tilli1, G. Fiorentini2 - 1Delta Hospital Ferrara, Ferrara, Italy, 2General Hospital Empoli, Empoli, Italy. A2. A Phase III Study Comparing TACE-DC Beads IRI Loaded (DEBIRI) with FOLFIRI Chemotherapy (CT) for Patients with Nonresectable Colorectal Cancer (CRC) Liver Metastases (LM) C. Aliberti1, G. Benea1, R. Rizzati1, R. Righi1, M. Tilli1, I. Marri1, G. Fiorentini2 - 1Delta Hospital Ferrara, Ferrara, Italy, 2Empoli General Hospital, Empoli, Italy. A3. A Phase II Clincial Trial on Hepatic Intra-arterial Injection of Yttrium-90 Microspheres in Unresectable Heavily Pre-treated Colorectal Liver Metastases 8.6mb L. Carpanese1, G. Pizzi1, R. Golfieri2, F. Fiore3, D. Gasparini4, C. L. Maini1, R. Sciuto1, M. Cosimelli1 - 1IFO Istituto Regina Elena National Cancer Institute, Roma, Italy, 2Ospedale S.Orsola Malpighi, Bologna, Italy, 3Fondazione G. Pascale National Cancer Institute Discussion (10 minutes)
10:00 am - 10:30 am		Coffee Break (Exhibit Hall)
10:30 am - 11:45 am		Multimodality Session II: Co-Chairs: Yuman Fong, Mike Wallace & Alice Gillams NON-COLORECTAL LIVER METASTASES (15 min. presentations) 1. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Medical Management And Rationale for Loco-Regional Therapy 6.4mb Al Benson 2. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Surgical Management 17.4mb Yuman Fong 3. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Transarterial Therapy 1mb Michael Wallace 4. Neuroendocrine and Other Non-Colorectal Hepatic Metastases: Ablative Therapy 170mb Alice Gillams 5. Selected ASCO/WCIO Abstract (5 Minute Presentation with 5 minute discussion at the end of the abstracts) A4. Treatment of Intrahepatic Cholangiocarcinoma Using Y90 Radioactive Microspheres: A Single Institutional Experience 1.75mb S. M. Ibrahim, M. F. Mulcahy, R. J. Lewandowski, K. T. Sato, A. Benson III, R. Salem; Northwestern University, Chicago, IL. Discussion (5 Min.)
11:45 am - 12:30 pm		Multimodality Session III: LIVER METASTASES TUMOR BOARD 77.6mb Co-Chairs: Bill Lees, Al Benson, Yuman Fong
12:30 pm - 1:30 pm		Lunch Break & Poster Viewing
1:30 pm - 3:30 pm		Basic Science and Technology Session I: Co-Chairs: Stephen Solomon & Fred Lee ADVANCES IN ENERGY BASED AND EMBOLIC THERAPIES (10 min. presentations) Tissue Ablation: 1. Basic Science and Advances in Thermal Ablation 3.3mb Chris Brace 2. Basic Science and Advances in Cryotherapy 11.5mb Peter Littrup 3. Basic Science and Advances in HIFU 52.5mb Stephen B. Solomon 4. Basic Science and Advances in Irreversible Electroporation 17.8mb Boris Rubinsky 5. Stereotactic radiosurgery/IMR/IGRT 12.6mb Thomas Mackie Trans-arterial Therapy: 6. Biology and Advances in Drug Eluting Beads 7mb Peter Stratford 7. Radio-Embolization: Foundation and Future 44mb Andrew Kennedy 8. New Intra-Arterial Chemotherapeutics 25.8mb Jeff Geschwind 9. Oncolytic Viruses and Novel Agents 26mb Anthony Reid 10. Selected ASCO/WCIO Abstract (5 Minute Presentations with 10 minute discussion at the end of the abstracts) A5. Microwave Ablation: Multiple-antennas Spatially Distribute Power and Significantly Improve Thermal Profiles While Potentially Reducing Invasiveness P. F. Laeseke, D. W. van der Weide, F. T. Lee, Jr, C. L. Brace; University of Wisconsin, Madison, WI. A6. Low-frequency RF Ablation: Ex-vivo Studies to Demonstrate Preferential Heating of Tumors 1.7mb D. J. Schutt1, S. Shah2, P. Guion2, B. J. Wood2, D. Haemmerich1; 1Medical University of South Carolina, Charleston, SC, 2NIH, Bethesda, MD. A7.Tumor Ablation with a Hybrid Cryotherapy and Radiofrequency System using a Gas-Cooled Probe - Results of an Ex-vivo Application Study 3.6mb H. Rempp1, M. Voigtländer2, S. Kempf1, A. Neugebauer2, S. Clasen1, C. Schraml1, C. D. Claussen1, M. D. Enderle2, N. S. Goldberg3, P. L. Pereira1; 1University of Tübingen, Tübingen, GERMANY, 2ERBE Elektromedizin, Tübingen, GERMANY, 3Beth Israel Deaconess Medical Center, Boston, MA. A8.Microbubble Platform for Non-invasive US-mediated Drug Delivery to Liver Tumors: In-vivo Evaluation 2.45mb J. Eisenbrey1, M. A. Wheatley1, M. C. Soulen2; 1Drexel University, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA. A9.Preliminary Study of Ultrasound Image-guided High Intensity Focused Ultrasound (HIFU) Treatment for Solid Tumors in an European Comprehensive Cancer Center 14.5mb F. Orsi1, P. Arnone1, L. Zhang2, P. Della Vigna1, L. Monfardini1, G. Bonomo1, K. Zhou2, W. Chen2, Z. Wang2; 1European Institute of Oncology, Milan, Italy, 2Clinical Center for Tumor Therapy of 2nd Hospital of Chongqing University of Medical Sciences, Chongqing, China. Discussion (10 Min.)
1:30 pm - 3:30 pm		Concurrent ONCOLOGY SESSION I: BEST OF ASCO 1.  Welcome and Introductions - Mark Pegram, Masakatsu Toi   2.  Gastrointestinal Colorectal Cancers 5.8mb - Al Benson Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials.   3.  Gastrointestinal Non-Colorectal Cancers 450kb - Jordan Berlin CONKO-001: Final Results of the randomized, prospective, multicenter phase 3 trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (PC) A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907) A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201   4.  Genitourinary Cancers 3.9mb - William Figg RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-3 study Radiotherapy versus Carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214) Abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, has significant and durable anti-tumor activity in both chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC) Impact of Androgen Deprivation Therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients
3:30 pm - 4:00 pm		Refreshment Break (Exhibit Hall)
4:00 pm - 5:30 pm		IO TREATMENT STRATEGIES Session I: LIVER METASTASES Co-Chairs: Riad Salem & Fred Lee Percutaneous ablation of liver metastases: (10 min. presentations) 1. Patient Selection and Anatomic Considerations 7.67mb Fred Lee 2. Optimizing RFA Technique 8.3mb Alice Gillams 3. Ct/Us In Ablation Guidance and Monitoring 105mb Louis Hinshaw 4. Post Ablation Imaging and Management 15mb Philippe Pereira Transcatheter therapy of liver metastases: (7 min. presentations) 1. Portal Vein Embolization 15.6mb David Madoff 2. Bland Embolization 5.7mb Karen Brown 3. Chemoembolization 17.9mb Daniel Sze 4. Radioembolization 2.75mb Jose Bilbao 5. Chemo-infusion 2.5mb Yasuaki Arai 6. Debate on Trans-arterial Techniques
4:00 pm - 5:30 pm		Concurrent ONCOLOGY SESSION II: BEST OF ASCO 1.  Breast Cancer - Local Regional Adjuvant Therapy – 1mbPeter Ravdin Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12 Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907 Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC) Zoledronic Acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809   2.  Breast Cancer - Metastatic 7.2mb - Mark Pegram Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series   3.  Melanoma 4.5mb - Donald Morton Final results of the Sunbelt Melanoma Trial Sentinel lymph node biopsy (SLNB) improves survival among SEER patients with melanoma
6:00 pm - 7:30 pm		Welcome Reception
7:30 pm - 9:30 pm		AngioDynamics Symposium - Novel Thermal and Non-Thermal Ablation Techniques in the Management of Malignancies
MONDAY, June 23, 2008
7:00 am - 8:00 am		Ablation Workshop
8:00 am - 10:00 am		Multimodality Session IV: LUNG MALIGNANCIES Co-Chairs: Steven Rose, Thomas DePetrillo, Hiran Fernando, Lyudmila Bazhenova NON-SMALL CELL LUNG CANCER (15 min. presentations) 1. NSCLC: Overview of Staging and Medical Therapy 1.8mb Lyudmila Bazhenova 2. NSCLC: Surgical Resection, Indication and Results 9.3mb Hiran Fernando 3. NSCLC: Percutaneous RFA: Indication and Results 5mb Steven Rose 4. NSCLC: Alternative Ablative Therapies 13.3mb Damian Dupuy 5. NSCLC: Radiation Therapy with/without Ablation: Indications and Results 18.6mb Tom Dipetrillo 6. Selected ASCO/WCIO Abstract (5 Minute Presentation with 2 minute discussion at the end of the abstract) A10.RFA Following EBRT Improves Survival of NSCLC in Bangladesh 38.2mb A. S. Murshed - American SuperSpecialty Hospital Ltd, Dhaka, Bangladesh. Discussion (2 Min.) LUNG METASTASES (15 min. presentations) 7. Lung Metastases: Role of Surgical Resection 16mb Garrett Walsh 8. Lung Metastases: Role of Ablative Therapy 8.48mb Koichiro Yamakado 9. Selected ASCO/WCIO Abstract (5 Minute Presentation with 2 minute discussion at the end of the abstract) A11. Clinicial Study on Targeted Argon-Helium Cryotherapy in Treatment for 725 Cases with Pulmonary Neoplasms H. S. Feng; Navy General Hospital, Beijing, China. Discussion (2 Min.)
10:00 am - 10:30 am		Coffee Break (Exhibit Hall)
10:30 am - 11:00 am		Multimodality Session V: LUNG TUMOR BOARD 8.87mb Co-chairs: Damian Dupuy, Roberto Orrechia, Garrett Walsh
11:00 am - 12:00 pm		Multimodality Session VI: BONE METASTASES AND PAIN PALLIATION Co-Chairs: Matthew Callstrom & Nora Janjan (10 min. presentations) 1. Medical and Surgical Management and Rationale for Loco-regional Therapies 9.6mb Thomas Smith 2. Radiation Therapy of Painful Bone Metastases 821kb Nora JanJan 3. RFA of Painful Bone Metastasis 34.5mb Damian Dupuy 4. Cryoablation and Stabilization of Painful Bone Metastases 87.5mb Matthew Callstrom 5. Ablation and Stabilization of Vertebral Body Tumors 35.9mb Afsin Gangi 6. Selected ASCO/WCIO Abstract and/or Q&A (5 Min. Presentations followed by 5 min. discussion) A12.Percutaneous Cryotherapy of Soft Tissue (Non-organ) Metastases: Potential for Local Control with Low Morbidity as a Flex Adjunct to Systemic Therapy 2.67mb P. J. Littrup1, H. D. Aoun2, D. Cyriac2, B. A. Adam1 - 1Karmanos Cancer Center, Detroit, MI, 2Wayne State University, Detroit, MI. Discussion (2 min.)
12:00 pm - 12:30 pm		Keynote Speaker Molecular Diagnostics: Key to Molecular Therapies 21.7mb Michael Phelps, UCLA Molecular & Medical Pharmacology
12:30 pm - 1:30 pm		Lunch Break & Poster Viewing (Exhibit Hall)
1:30 pm - 3:30 pm		Basic Science and Technology Session II: ADVANCES IN IMAGE GUIDANCE AND MONITORING Co-Chairs: Philippe Pereira, Luigi Solbiati, Bradford Wood (15 min. presentations) 1. Advances in Interventional US (Contrast Agents, Real-time Fusion Imaging) 205mb Luigi Solbiati 2. Advances in 3D Fluoroscopy 27.8mb Marshall Hicks 3. Advances in Interventional CT Thomas Helmberger 4. Advances in Interventional MRI (guidance, monitoring, assessment) 15.2mb Philippe Pereira 5. Newest Technological Advancements (Multimodality Imaging, Robotics) Bradford Wood 6. Role of Molecular Imaging in Image Guided Intervention 7.9mb Johannes Czernin 7. Selected Abstracts (5 Minute Presentations with 10 minute discussion at the end of the abstracts) A13.CT-fluoroscopic Imaging of Ablation Zone Growth: Improved Visualization with Periodic Contrast Injections and HYPR Reconstruction 2.3mb C. L. Brace, C. A. Mistretta, P. F. Laeseke, L. A. Sampson, J. Hinshaw, F. T. Lee, Jr - University of Wisconsin, Madison, WI. A14.Relationships Between Ablative Margin and Local Tumor Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Three-dimensional Quantitative Analysis Using CT Image Fusion and Multi-planar Reformatting 44.6mb Y. Kim, W. Lee, H. K. Lim, H. Rhim, D. Choi; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. A15.High-Intensity Ultrasound Ablation of the Canine Prostate: Monitoring and Post-Procedural Assessment with Magnetic Resonance Imaging 4.1mb V. Rieke1, J. Chen1, A. B. Holbrook1, D. M. Bouley1, C. J. Diederich2, G. Sommer1, K. Butts Pauly1; 1Stanford University, Stanford, CA, 2UCSF, San Francisco, CA. Discussion (10 min.)
1:30 PM - 3:30 PM		Concurrent ONCOLOGY SESSION III: BEST OF ASCO 1.  Lung Cancer 5.3mb - David Gandara S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212) FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study   2.  Patient and Survivor Care 3.5mb - Patricia Ganz A Phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer Cardiovascular disease in adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study (CCSS) Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multi-modality cohort study   3.  Gynecologic Cancers 6.5mb - Maurie Markman Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology AZD2281 (KU-0059436), a PARP (Poly ADP-ribose Polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a Phase I study
3:30 pm - 4:00 pm		Refreshment Break (Exhibit Hall)
4:00 pm - 5:30 pm		IO TREATMENT STRATEGIES Session II: LUNG AND METASTATIC BONE TUMORS Lung Tumors: Co-Chairs: Robert Suh, Steven Rose (15 min. presentations) 1. Patient Selection and Evaluation 325kb Karin Steinke 2. Optimizing Ablative Technique 36.4mb Damian Dupuy 3. Clinical and Imaging Follow-up 9mb Robert Suh 4. Complications and Management 46.2mb Kamran Ahrar Bone and Soft Tissue Tumors (15 min. presentations) Chair: William Charboneau 5. Vertebral Body 12.3mb Afshin Gangi 6. Bone 112mb William Charboneau
4:00 pm - 5:30 pm		Concurrent ONCOLOGY SESSION IV: BEST OF ASCO 1.  Lymphoma/Leukemia/Myeloma 4.8mb – Michael Lill & Robert Vescio Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF) Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) Total therapy (TT) for myeloma (MM): 10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 Bortezomib/Dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial   2.  Developmental Therapeutics - Andrew Dorr 2mb A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors
6:00 pm - 8:00 pm		Industry Symposium Multidisciplinary Management of Hepatocellular Carcinoma Sponsored by Educational Concepts Group and supported by an educational grant from Bayer Healthcare and Onyx Pharmaceuticals
TUESDAY, June 24, 2008
7:00 am - 8:00 am		Image Guidance Workshop
8:00 am - 10:00 am		Multimodality Session VII: HEPATOCELLULAR CARCINOMA Co-Chairs: Riccardo Lencioni, Ronald Busuttil, Jeff Geschwind, Myron Tong (10 min. presentations) 1. Clinical Overview and Natural History 423kb Myron Tong 2. Surgical Resection: Patient Selection and Outcomes 5.1mb Nicolas Vauthey 3. Transplantation: Patient Selection and Outcomes 15.5mb Ronald Busuttil 4. TAE/TACE: Indications and Outcomes 288kb William Rilling 5. TACE with Drug Eluting Beads 3mb Jeff Geschwind 6. Radioembolization: Indications and Outcomes Riad Salem 7. Percutaneous Chemical Ablation: Indications and Outcomes 7.3mb Michael Soulen 8. Percutaneous Thermal Ablation: Indications and Outcomes 4mb Gerald Dodd 9. Role of Loco-regional Therapies as Bridge to Transplant 3mb David Lu 10. Combining Transarterial and Ablative Therapies 3mb Riccardo Lencioni 11. Integrating HCC Management with Loco-regional and Advances in Systemic Therapies 3.4mb TBD 12. Q & A
10:00 am - 10:30 am		Coffee Break (Exhibit Hall)
10:30 am - 11:00 am		Multimodality Session VIII: HEPATOCELLULAR CARCINOMA (CONTINUED) 13. Selected ASCO/WCIO Abstracts (5 Minute Presentations with 10 minute discussion at the end of the abstracts) A16.TACE Sequentially Combined with RFA and CIKS infusion for HCC 65.3mb P. Wu, J. Xia, M. Zhao, Q. Zhou, Q. Wang, L. Huang, Y. Li, S. Chen - Sun Yat-sen University, Guangzhou, China. A17.Percutaneous Thermal Ablation Treatment for Medium and Large Hepatocellular Carcinoma: Long-term Outcome and Prognostic Factors 2.8mb M. Kuang, X. Yin, X. Xie, M. Lu - The first Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. A18.Does Neoadjuvant Therapy for HCC Decrease Dropout Rates Among Patients Listed for OLT? 636kb M. Vella, K. Olthoff, A. Shaked, R. Reddy, M. Rosen, M. C. Soulen - University of Pennsylvania, Philadelphia, PA. A36.Evaluation of Drug Loadable Porous Microspheres for Doxorubicin Delivery: Vx-2 Tumor Model in Rabbit Liver 52.6mb Kwang-Hun Lee, Eleni A. Liapi, Manon Buijs, Josephina A Vossen, Veronica Prieto Ventura, Kelvin Hong, Christos S Georgiades, Jean-Francois H. Geschwind Discussion (10 Min.)
11:00 am - 12:00 pm		Multimodality Session IX: HCC INTERNATIONAL TUMOR BOARD 991kb Co-Chairs: Riccardo Lencioni, Jordan Berlin, Marisato Sato, Nicolas Vauthey
12:00 pm - 12:30 pm		Keynote Lecture Image Guided Therapy in the Genomic Era 31.9mb King C. Li, MD, The Methodist Hospital, Department of Radiology
12:30 pm - 1:30 pm		Lunch Break & Poster Viewing (Exhibit Hall)
1:30 pm - 3:30 pm		IO TREATMENT STRATEGIES Session III: TRANSARTERIAL THERAPY FOR HCC Co-Chairs: William Rilling, Yasuaki Arai, Ren-jie Yang (15 min. presentations) 1. Clinical Evaluation and Patient Selection in Transarterial Therapies for HCC 3.9mb William Rilling 2. HCC Treatment Planning and Endpoint Determination with CTA and CTAP 7.4.mb Yasuaki Arai 3. TACE for HCC: Optimizing Technique 6.8mb Jae-Hyung Park 4. TACE and Interventional Management in Advanced, Complicated HCC 11.1mb Ren-jie Yang 5. Y 90 Radioembolization for HCC: Optimizing Technique 30.4mb Jose Bilbao 6. Complications and Management of Transarterial Therapies 5.2mb Daniel Brown 7. Post Therapy Imaging and Follow Up: 19mb a. Post TAE/TACE and Radioembolization Robert Lewandowsky 8. Selected Abstracts (5 Minute Presentations with 5 minute discussion at the end of the abstracts) A19.Actual Survival Following Chemoembolization for Hepatocellular Carcinoma in a U.S. Center: Correlation with Prognostic Systems 106kb A. Weiss1, M. C. Soulen2, S. W. Stavropoulos2, J. I. Mondschein2, A. A. Patel2 - 1University of Pennsylvania, Philadlephia, PA, 2University of Pennsylvania, Philadelphia, PA. A20.The Significance of Alpha-Fetoprotein Reduction After Y90 Radioembolization for Unresectable Hepatocellular Carcinoma: A Subgroup Comparison of Producers Versus Nonproducers 2.6mb R. K. Ryu, S. Ibrahim, R. J. Lewandowski, R. A. Omary, K. T. Sato, R. Salem - Northwestern University, Chicago, IL. Discussion (5 Min.)
1:30 pm - 3:30 pm		Concurrent ONCOLOGY SESSION V: TISSUE GENE/MOLECULAR PROFILING & TARGETTED THERAPIES Co-Chairs: Mark Pegram, Gary Dorfman, James Economou 1. Introduction an Oncologic Overview 6.7mb Mark Pegram 2. What is the Opportunity, What Are the Barriers 2mb Gary S. Dorfman 3. Advances in Biopsy Techniques Brad J. Wood 4. Advances in Biospecimen Analysis and Its Role in Guiding Targeted Therapies Richard J. Cote 5. Linking In Vitro and In Vivo Data: Imaging Phenotypes Michael Kuo 6. Panel Discussion, Q & A
3:00 pm - 4:00 pm		Refreshment Break (Exhibit Hall)
4:00 pm - 5:30 pm		IO TREATMENT STRATEGIES Session IV: ABLATIVE THERAPY FOR HCC Co-Chairs: Gerald Dodd & Hyo Keun Lim (10 min. presentations) 1. Imaging Criteria and Biopsy in Diagnosis of HCC 112mb Steve Raman 2. Alcohol Ablation - Optimizing technique 13.6mb Chia Sing Ho 3. Thermal Ablation - Optimizing Technique 22.8mb Hyuncul Rhim 4. Advanced Ablation Strategies in Difficult Cases 2mb David Lu 5. Complications and Management of Percutaneous Ablations 7mb Gerald Dodd 6. Post RFA Imaging 105mb Hyo Keun Lim 7. Selected Abstracts and/or Q&A (5 Minute Presentations with 10 minute discussion at the end of the abstracts) A21. Treatment of Malignant Liver Tumors with Percutaneous Microwave Ablation: Experience with Complications in 1136 Patients P. Liang, Y. Wang, X. Yu, Y. Gao, H. Ren - Department of Ultrasound, PLA general hospital, Bejing, China. A22. Treatment Strategy and Efficacy of Radiofrequency Ablation in 172 Patients with 3.5 Hepatocellular Carcinoma W. Yang, M. Chen, W. Wu, Y. Fu, J. Wu, Y. Hou, K. Yan - The School of Oncology, Peking University, Beijing, China. A23. Percutaneous Ethanol Injection of Hepatocellular Carcinoma with Single Treatment Session by Using a Multi-pronged Injection Needle X. XIE, M. KUANG, M. LU - The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China, Guangzhou, China. Discussion (10 Min.)
4:00 pm - 5:30 pm		Concurrent ONCOLOGY SESSION VI: Co-Chairs: Gary Dorfman & Mark Pegram 1. Percutaneous Trials In North America and Europe 913kb Riccardo Lencioni 2. Transvascular Trials In North America and Europe 463kb Marshal Hicks 3. MR Guided Focused Ultrasound Trials Worldwide 28.3mb David Gianfelice 4. Percutaneous and Transvascular Trials In Japan and Asia 724kb Yasuaki Arai
5:30 pm - 6:30 pm		Focus Session: Bridge to China 2009 Co-Chairs: Ren Jie Yang, David Lu (7 min. presentations) 1. New advances of microwave ablation in China Ping Liang 2. RFA vs surgery in the treatment of small HCC 1.9mb Dr. Kuang 3. Role of RFA in the treatment of large HCC 11.3mb W. Yang 4. Ethanol ablation of HCC with multi-pronged injection 19.9mb Xiao Yan Xie 5. TACE in prevention and treatment of postoperative recurrence of HCC Sheng Long Ye 6. TAE with iodized oil and pingyangmycin for hemangiomas of liver 2.7mb Su Hongying 7. Percutaneous cryoablation of non small cell lung cancer Ji Ren Zhang
WEDNESDAY, June 25, 2008
7:00 am - 8:00 am		Transarterial Therapy Workshop
8:00 am - 10:00 am		Multimodality Session X: GENITOURINARY MALIGNANCIES Co-Chairs: Debra Gervais, Surena Matin, Peter Mueller Renal Cell Carcinoma and Renal Masses (10 min. presentations) 1. Clinical Overview and Natural History 4.7mb Robert Figlin 2. Systemic Therapy 1.9mb Robert Figlin 3. Surgical Resection 45mb Surena Matin 4. RFA for RCC 5mb David Breen 5. Cryoablation for RCC 10mb William Charboneau 6. Transcatheter Embolization of Renal Masses 46.2mb Kamran Ahrar IO in Other GU Malignancies (10 min. presentations) 7. Percutaneous Adrenal Ablation 2.2mb William Mayo-Smith 8. Regional Radiation Therapy for Prostate Cancer 10.6mb Thomas DiPetrillo 9. Focal Ablative Therapy for Prostate Cancer 8mb Gary Onik 10. Role of Ablation in Ovarian Cancer 8mb Debra Gervais 11. Selected ASCO/WCIO Abstract and/or Q&A (5 Minute Presentations with 5 minute discussion at the end of the abstracts) A24. Laparoscopic RFA for Small Renal Masses: Initial Clinical Series S. Williams, R. Leveillee, M. Wingo, V. Bird - University of Miami, Miami, FL. A25.Percutaneous Cryotherapy of Renal Cell Carcinoma (RCC): Low Complication and Recurrence Rates Beyond 12 Months 3.6mb P. J. Littrup1, H. D. Aoun2, B. A. Adam1 - 1Karmanos Cancer Center, Detroit, MI, 2Wayne State University, Detroit, MI. A26.Nephron-sparing Radiofrequency Ablation of Renal Cell Carcinoma in Patients with a History of Contra-Lateral Nephrectomy: Initial Clincial Experience 3.4mb W. Prevoo, M. A. van den Bosch, F. van Coevorden, S. Horenblas - The Netherlands Cancer Institute, Amsterdam, The Netherlands. Discussion (5 Min.)
10:00 am - 10:30 am		Coffee Break (Exhibit Hall)
10:30 am - 11:00 am		Multimodality Session XI: GENITOURINARY TUMOR BOARD Co-Chairs: Kamran Ahrar & Surena Matin
11:00 am - 12:30 pm		MULTIMODALITY SESSION XII: EXPLORING SYNERGIES: SYSTEMIC, LOCAL/REGIONAL, ENERGY, DRUGS, AND BIOLOGIC AGENTS 74mb Co-Chairs: S. Nahum Goldberg, Thomas DiPetrillo, Keith Stuart, Michael Soulen (10 min. presentations) 1. Antiangiogenesis and Minimal Invasive Therapy 3.2mb Robert Figlin 2. Enhancing Anti-tumoral Efficacy by Transarterial Delivery 5.5mb Michael Soulen 3. Targetted Energy Activation and Systemic Agents 16.9mb S. Nahum Goldberg 4. Thermal Ablation and Radiation Therapy 14.3mb Tom DiPetrillo 5. Immunologic Modulation and Interventional Oncology 26.7mb Elizabeth Repasky 6. The Case for Adding Focal Therapy to Medical Oncology Practice 121mb Keith Stuart 7. Selected abstracts and/or Q&A (5 Minute Presentations with 10 minute discussion at the end of the abstracts) A27.Phase I Dose Escalation Study of Thermally Sensitive Lipsomal Doxorubicin (Thermodox) in Combination with Radiofrequency Ablation (RFA) of Primary and Metastastic Tumors to the Liver: Interim Report 4.2mb T. S. Ravikumar1, K. Fehn1, R. Prabhakar2, N. Borys2, C. Black2 - 1NS-LIJ Health System, New Hyde Park, NY, 2Celsion Corporation, Columbia, MD. A28.A Phase II Study of Selective Internal Radiation Treatment (SIRT) and Selective External Radiation Treatment (SERT) with Chemotherapy in Patients with Recurrent/Metastatic Pancreatic Cancer 866kb M. J. Hall, K. Pennington, S. Gulec - Goshen General Hospital, Goshen, IN. A29.Direct Intratumoral Therapy of Human Squamous Cell Carcinoma in a Rat Model: Comparison of Efficacy of Combinations of Doxil, Liposome Encapsulated 186Re. and Radiofrequency Ablation 4mb X. Garcia-Rojas, A. Bao, W. T. Phillips, A. Soundararajan, B. Goins, G. D. Dodd III - University of Texas Health Science Center at San Antonio, San Antonio, TX A30.A Pilot Study of Intravenous Bevacizumab in Hepatocellular Cancer Patients Undergoing Chemoembolization 1.7mb C. D. Britten1, A. Gomes1, N. Bucher1, R. Amado1, L. Yonemoto1, G. Bentley1, R. Mass2, R. W. Busuttil1, D. J. Slamon1, R. S. Finn1 - 1David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Genentech, South San Francisco, CA. Discussion (10 Min.)
12:30 pm - 1:30 pm		Lunch And Poster Viewing (Exhibit Hall)
1:30 pm - 2:30 pm		Multimodality Session XIII: Emerging IO Applications Co-Chairs: John McGahan & Ross Abrams (10 min. presentations) 1. Chemo-embolization Beyond Liver 36.4mb Thomas J. Vogl 2. Emerging Thermal Ablation Applications 78.5mb John McGahan 3. Emerging Cryo-ablation Applications 8mb Peter Littrup 4. Emerging IMRT Applications 3.9mb – Ross Abrams 5. HIFU Beyond Fibroids 28.7mb – David Gianfelice 6. Irreversible Electroporation: Early Tumor Data 432mb Stephen Kee
2:30 pm - 3:30 pm		Multimodality Session XIV Co-Chairs: John McGahan & Ross Abrams A31.Irreversible Electroporation (IE): A Novel Non-thermal Tumor Ablation Technique Resulting in Apoptotic Cell Death 13.2mb E. W. Lee, S. T. Kee, C. T. Loh, V. E. Prieto, J. D. Grant - UCLA Medical Center, Los Angeles, CA. A32.Management of Painful Acetabular Metastases by Combined Radiofrequency Ablation and Osteoplasty 3.7mb S. S. KULKARNI, A. V. KULKARNI, A. R. BHALEKAR, D. ROY, M.H. Thakur - TATA MEMORIAL HOSPITAL, MUMBAI, INDIA. A33.Cryotherapy for Benign and Cancerous Breast Tumors: US and CT-guidance 3.4mb P. J. Littrup, L. Freeman-Gibb, B. Adam - Karmanos Cancer Center, Detroit, MI. A34.Prognostic Impact of Dose and Selection in Thoracic Stereotatic Radiotherapy. Retrospective Analysis of 175 Treatments 1.8mb G. Catalano1, F. Serafini1, G. Piperno1, R. Lazzari1, C. Garibaldi2, R. Cambria2, B. Tagaste2, P. Fossati1, M. Ciocca2, R. Orecchia3 - 1Radiotherapy Division, European Institute of Oncology, Milan, Italy, 2Medical Physic Unit, European Institute of Oncology, Milan, Italy, 3Chair of Radiotherapy University Milan, European Institute of Oncology, Milan, Italy. A35.Rolse of Embolization prior to Cryoablation of Large Renal Tumors D. A. Woodrum, T. D. Atwell, M. A. Farrell, M. R. Callstrom, J. C. Andrews, W. Charboneau - Mayo Clinic, Rochester, MN. A36.An Apoptotic Enhancer Liposomal Paclitaxel Dramtically Increases RF Induced Coagulation in the R3230 Rat Tumor Model 6.2mb S. N. Goldberg1, E. A. Abd El Hady1, E. M. Mostafa1, T. Levchenko2, V. Torchillin2, S. Signoretti3 - 1Beth Israel Deaconess Medical Center, Boston, MA, 2Northeastern University, Boston, MA, 3Brigham and Women's Hospital, Boston, MA. A37.Controlled Radiofrequency Hyperthermia and Simultaneous Monitoring of its Effects in Sc-implanted 9L-glioma by In Vivo 1H, 23Na and 31P Magnetic Resonance Spectroscopy 2.2mb J. R. James, Y. Gao, V. C. Soon, S. M. Topper, A. Babsky, N. Bansal - Department of Radiology, Indiana University School of Medicine, Indianapolis, IN.
3:30 pm - 4:00 pm		Refreshment Break (Exhibit Hall)
4:00 pm - 5:30 pm		IO TREATMENT STRATEGIES Session V: GU Tumors Co-Chairs: Debra Gervais, Steve Raman, Stuart Silverman (15 min. presentations) 1. Treatment Planning 13.9mb Steve Solomon 2. Biopsy or No Biopsy Before Ablation 11.3mb Stuart Silverman 3. Cryoablation versus RF Ablation for Renal Masses 24.8mb Steve Raman 4. Size Matters: Upper and lower Limits of Renal Mass Ablation 3.5mb Ronald Zagoria 5. Avoiding and Managing Complications of Renal Ablation 15.9mb Peter Mueller 6. Imaging Follow Up after Renal Ablation: Basic Premises and Current Challenges 12.1mb Debra Gervais
4:00 pm - 5:30 pm		IO TREATMENT STRATEGIES Session VI: PRACTICE DEVELOPEMENT Co-Chairs: Daniel Brown & Riad Salem (10 min. presentations) 1. How to Set Up an IO Clinic 1.1mb David Liu 2. Role of Physician Extenders 751kb Kelvin Hong 3. Managing an Inpatient Interventional Oncology Service 700kb Tim Clark 4. Practice Building 1.1mb Daniel Brown 5. What’s New in Reimbursement 136kb Catherine Tuite 6. Q&A
5:30 pm		Adjourn